心脏保护研究室

研究方向：心肌细胞损伤和保护措施。

基金情况：

物种内和物种间心脏与肝脏再生的分子调控网络及其异同机制研究。科技部国家重点研发计划；项目编号：2018YFA0800500；起止日期：2019/7-2024/6；子课题负责人；经费：519万元（子课题经费，个人经费167.61万元）；在研。

工作人员：刘雅涵 助理研究员；李盈佳 主管技师

在读研究生情况：

卢珊，张文佳

主要发表论文情况：

1. Song Y, Xu C, Liu J, Li Y, Wang H, Shan D, Wainer I, Hu X, Zhang Y（张岩）^†, Woo YH^†, Xiao RP. Heterodimerization with 5-HT2BR Is Indispensable for b2AR-mediated Cardioprotection. Circ Res, 2020, Online ahead of print. (^†共同通讯作者,影响因子14.5).

2. Shan D, Guo S, Wu HK, Lv F, Jin L, Zhang M, Xie P, Wang Y, Song Y, Wu F, Lan F, Hu X, Cao CM^†, Zhang Y（张岩）^†, Xiao RP^†. Cardiac Ischemic Preconditioning Promotes MG53 Secretion through H₂O₂-activated PKC-d Signaling. Circulation, 2020, 142, 1077-1091. (^†共同通讯作者,影响因子23.6).

3. Zhang M, Gao H, Liu D, Zhong X, Shi X, Yu P, Jin L, Liu Y, Tang Y, Song Y, Liu J, Hu X, Li CY, Song L, Qin J, Wu F, Lan F, Zhang Y（张岩）^†, Xiao RP. CaMKII-9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair. Nat Cell Biol, 2019, 21, 1152-1163. (^†独立通讯作者,影响因子20.0).

4. Wu HK*, Zhang Y（张岩）*, Cao CM*, Hu X, Fang M, Yao Y, Jin L, Chen G, Jiang P, Zhang S, Song R, Peng W, Liu F, Guo J, Tang L, He Y, Shan D, Huang J, Zhou Z, Wang D, Lv F, Xiao RP. Glucose-sensitive Myokine/Cardiokine MG53 Regulates Systemic Insulin Response and Metabolic Homeostasis. Circulation, 2019, 139, 901-914. (*共同第一作者,影响因子23.6).

5. Zhang J, Liu D, Zhang M, Zhang Y（张岩）^†. Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond. Br J Pharmacol. 2019, 176, 4319-4339. (^†独立通讯作者，影响因子7.7).

6. Wang Y, Jin L, Song Y, Zhang M, Shan D, Liu Y, Lv F, Xiao RP, Zhang Y（张岩）^†. β-arrestin 2 mediates cardiac ischemia-reperfusion injury via inhibiting GPCR-independent cell survival signaling. Cardiovasc Res. 2017, 113, 1615-1626. (^†独立通讯作者，影响因子8.2).

7. Zhang Y（张岩）, Wu HK, Lv F, Xiao RP. MG53: biological function and potential as a therapeutic target. Mol Pharmacol. 2017, 92, 211-218. (第一作者，独立通讯作者，影响因子3.7).

8. Zhang T*, Zhang Y（张岩）*^†, Cui M, Jin L, Wang Y, Lv F, Liu Y, Zheng W, Shang H, Zhang J, Zhang M, Wu HK, Guo J, Zhang X, Hu X, Cao CM, Xiao RP^†. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 2016, 22, 175-182. (*共同第一作者, ^†共同通讯作者，影响因子36.1).

9. Zhang Y（张岩）, Zheng W, Liu Y, Wang J, Peng Y, Shang H, Hou N, Hu X, Ding Y, Xiao Y, Wang C, Zeng F, Mao J, Zhang J, Ma D, Sun X, Li C, Xiao RP, Zhang X. Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome. Sci Rep. 2016, 6, 23957. (第一作者，影响因子4.0)

10. Zhu W, Tsang S, Browe, DM, Woo AY, Huang Y, Xu C, Liu JF, Lv F, Zhang Y（张岩）^†, Xiao RP^†. Interaction of β1-Adrenoceptor with RAGE Mediates Cardiomyopathy via CaMKII Signaling. JCI Insight. 2016, 1, e84969. (^†共同通讯作者，影响因子6.2).

11. Zhang Y（张岩）, Wu HK, Lv F, Xiao RP. MG53 is a double-edged sword for human diseases. Acta Physiologica Sinica. 2016, 68, 505-516 (第一作者，独立通讯作者).

12. Song RS*, Peng W*, Zhang Y（张岩）*, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, Zhang M, Jiang P, Liu F, Meng S, Zhang X, Jiang P, Cao CM, Xiao RP. Central Role of E3 Ubiquitin Ligase MG53 in Insulin Resistance and Metabolic Disorders. Nature, 2013, 494, 375-379 (*共同第一作者，影响因子42.8).

13. Zhang Y（张岩）*, Lv F*, Jin L, Peng W, Song RS, Ma J, Cao CM, Xiao RP. MG53 Participates in Ischemic Postconditioning through the RISK Signaling Pathway. Cardiovasc Res, 2011, 91, 108-115 (*共同第一作者，影响因子8.2).

14. Cao CM*, Zhang Y（张岩）*, Weisleder N*, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Takeshima H, Ma J, Xiao RP. MG53 Constitutes a Primary Determinant of Cardiac Ischemic Preconditioning. Circulation, 2010; 121: 2565-2574.

15. Peng W*, Zhang Y（张岩）*, Zheng M, Cheng H, Zhu W, Cao CM, Xiao RP. Cardioprotection by CaMKII-δB is Mediated by Phosphorylation of HSF1 and Subsequent Expression of Inducible HSP70. Circ Res, 2010; 106: 102-110 (*共同第一作者,影响因子14.5).